ORIGINAL RESEARCH article
Front. Cell Dev. Biol.
Sec. Cell Growth and Division
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1598705
The Role of IGF-2 and Its Variants in Enhancing Endothelial Migration and Angiogenesis
Provisionally accepted
- Biomedical Research Institute, Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Angiogenesis, the formation of new blood vessels, is essential for physiological processes such as tissue repair as well as pathological conditions including cancer. While insulin-like growth factor 2 (IGF-2) is identified as a key regulator of angiogenesis, the contributions of its variants remain less explored. Methods: We compared the effects of wildtype IGF-2 with that of Des(1-6)IGF-2, which has lower affinity to IGF-binding proteins (IGFBPs), and Leu27IGF2, which interacts selectively with the IGF-Receptor 2. We analyzed their effect on endothelial cell migration and tube formation as well as on the secretome of endothelial cells using an antibody array. In addition, the regulatory influence of IGFbinding protein 6 (IGFBP-6) in modulating these effects was investigated. Finally, the ability of the three different variants of IGF-2 to induce blood vessel formation was studied using the chicken 'chorioallantoic membrane' (CAM) assay. Results: IGF-2 and Des(1-6)IGF-2 significantly promoted endothelial cell migration and tube formation in vitro, while also increasing blood vessel formation in ovo. An angiogenesis antibody array revealed that these effects were mediated through the upregulation of several angiogenic proteins, including IL-6, uPAR, and MCP-1. Interestingly, Leu27IGF-2 exhibited a weaker effect, suggesting that IGF receptor 1 and/or insulin receptor activation plays a major role in these processes. IGFBP-6 effectively inhibits IGF-2-induced effects but has no impact on Des(1-6)IGF-2, highlighting the latter's ability to evade IGFBP-mediated inhibition due to structural modifications. Conclusion: These results suggest that Des(1-6)IGF-2 may serve as a potent pro-angiogenic agent with therapeutic potential, while IGFBP-6 could offer a strategy for suppressing pathological angiogenesis.
Keywords: IGF-2, IGF-2 variants, Angiogenesis, endothelial cell, Migration, Tube formation
Received: 23 Mar 2025; Accepted: 22 Apr 2025.
Copyright: © 2025 Alders, Pirlet, Gesquiere and Bronckaers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Annelies Bronckaers, Biomedical Research Institute, Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.